Make rare, high-cost treatment coordination accountable.
Connect the plan’s benefit terms, administrator and payer responsibilities, certified treatment centers and specialty coordination, including any contractually relevant stop-loss notification. No treatment delays, clinical decisions or reimbursement guarantees.
approximate cost per patient of the two sickle cell disease gene therapies examined in CMS’s Cell and Gene Therapy Access Model, per its first evaluation report (August 2026).
Limitation: A specific example. It is not a price range for every cell or gene therapy.
Source: CMS Innovation Center, CGT Access Model evaluation ↗Why it matters to self-funded plans
Cell and gene therapies are rare for any single plan, but each case can involve a certified treatment center, an administrator, a PBM or medical benefit, a stop-loss carrier and months of follow-up. Responsibilities are spread across parties that may not share one record.
Governance helps the plan see who acknowledged what and when, and whether contractual notifications were made.
What the plan may configure
Illustrative care destinations
The treating specialist and standard benefit processes stay available.
What partner response and encounter evidence should return
What must be validated first
This page describes an illustrative governance application, not a deployed pathway. Deployment depends on plan-specific applicability, partner capacity, authority and validated workflows. See current product maturity →
Start with the plan’s agreements and available claims.
The Control Tower assessment establishes the plan’s baseline and helps determine which care priorities may warrant governance.